Table 3.
PK Parameters (Mean±SD) for Pracinostat in Subjects with Hematologic Malignancies
| Dose (mg) | Cmax (ng/mL) | Tmax (h) | t1/2 (h) | AUC0-inf (ng·h/mL) |
|---|---|---|---|---|
| Day 1 | ||||
| 40 (n=6) | 84±34 | 1.1±0.7 | 9.4±3.5 | 434±191 |
| 60 (n=3) | 133±117 | 1.0±0.5 | 12.1±2.3 | 948±1143 |
| 80 (n=3) | 189±182 | 1.3±0.8 | 7.0±1.1 | 1047±803 |
| 100 (n=3) | 187±99 | 1.2±0.3 | 8.4±1.1 | 1171±347 |
| 120 (n=6) | 202±83 | 1.2±0.4 | 10.8±3.0 | 1356±725 |
| Day 15 | ||||
| 40 (n=5)* | 64±19 | 1.3±0.7 | 10.7±2.3 | 477±191 |
| 60 (n=3) | 118±135 | 0.8±0.3 | 11.8±3.4 | 766±746 |
| 80 (n=3) | 164±122 | 1.2±0.3 | 9.3±4.1 | 977±459 |
| 100 (n=3) | 314±143 | 1.0±0.5 | 13.7±5.6 | 1985±682 |
| 120 (n=2) | 96 | 1 | 14.1 | 757 |
Abbreviations: AUC0-inf: area under the concentration versus time curve from time 0 to infinity; Cmax: maximum concentration; PK: pharmacokinetics; SD: standard deviation; Tmax: time to maximum concentration; t1/2: half-life
*
PK parameters were not estimated from 1 subject as samples were not taken